DFE Pharma, headquartered in Goch, Germany, is a premier global provider of pharmaceutical and nutraceutical excipient solutions. Their portfolio includes functional excipients such as lactose, starch, and microcrystalline cellulose, utilized in oral solid dose (OSD), inhalation, parenteral, and biopharma formulations.

With a legacy spanning more than a century, the company serves over 5,000 customers across 100+ countries, supported by a dedicated workforce of approximately 450 professionals. 

The origins of DFE Pharma trace back to the merging of dairy-based lactose producers from the Netherlands and New Zealand, evolving into a leading excipient manufacturer. Since 2020, it has been jointly owned by Royal Friesland Campina and CVC Capital Partners, providing strong backing for growth and innovation. 

Their global operations include manufacturing and sales facilities across Europe, India, China, the US, and more, complemented by a Centre of Excellence in India—the "Closer to the Formulator" (C2F) facility in Hyderabad—which accelerates formulation development and technology transfer for oral solid dosage forms. 

DFE Pharma is committed to quality, following IPEC guidelines, ISO, GMP, and ICH Q7 standards across all sites. Their excipients function critically as fillers, binders, disintegrants, and stabilizers in drug delivery systems that improve patient outcomes.